Osteocalcin-directed gene therapy for prostate-cancer bone metastasis

Kenneth S. Koeneman, Chinghai Kao, Song Chu Ko, Ling Yang, Yoshitaka Wada, David F. Kallmes, Jay Y. Gillenwater, Haiyen E. Zhau, Leland W K Cluing, Thomas Gardner

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Osteocalcin (OC) is a major noncollagenous bone protein whose expression is limited almost exclusively to osteotropic tumors and mature calcified tissue (differentiated osteoblasts). The function of OC, a highly conserved gamma-carboxyglutamic acid-containing protein, relies in part on its ability to bind hydroxyapatite and act as a chemoattractant for bone-resorbing cells. Serum osteocalcin levels are used clinically as an index of active bone turnover. Research in our laboratory has revealed that OC is expressed in several solid tumors, including osteosarcoma and ovarian, lung, brain, and prostate cancers. Evidence arising from reverse-transcription polymerase chain reaction (RT-PCR; detection of OC mRNA), immunohistochemical staining (detection of OC protein), and transient transfection and reporter assay (detection of OC mRNA transcription) reveals that OC expression is up-regulated in numerous solid tumors, with its expression being further elevated in androgen-independent prostate cancers. A recombinant, replication-defective adenovirus, Ad-OC-TK (OC promoter-driven herpes-simplex-virus thymidine kinase) was constructed and, when combined with the appropriate prodrug, either ganciclovir (GCV) or acyclovir (ACV), was found to be effective at destroying prostate-cancer cell lines in vitro and prostate tumor xenografts in vivo in both subcutaneous and bone sites. Additionally, via use of the OC promoter the supporting bone stromal cells are cotargeted when the prostate cancer interdigitates with bone stroma at the metastatic skeletal sites. Thus, maximal tissue-specific cell toxicity is achieved by the interruption of cellular communication between the prostate cancer and the bone stroma. We describe herein the preclinical foundation as well as the design and implementation of an ongoing phase I clinical trial at the University of Virginia that targets androgen-independent metastatic prostate cancer using the Ad-OC-TK vector.

Original languageEnglish (US)
Pages (from-to)102-110
Number of pages9
JournalWorld Journal of Urology
Volume18
Issue number2
StatePublished - 2000
Externally publishedYes

Fingerprint

Bone Neoplasms
Osteocalcin
Genetic Therapy
Prostatic Neoplasms
Neoplasm Metastasis
Bone and Bones
Androgens
1-Carboxyglutamic Acid
Neoplasms
Polymerase Chain Reaction
Messenger RNA
Clinical Trials, Phase I
Ganciclovir
Proteins
Acyclovir
Thymidine Kinase
Bone Remodeling
Chemotactic Factors
Prodrugs
Osteosarcoma

ASJC Scopus subject areas

  • Urology

Cite this

Koeneman, K. S., Kao, C., Ko, S. C., Yang, L., Wada, Y., Kallmes, D. F., ... Gardner, T. (2000). Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World Journal of Urology, 18(2), 102-110.

Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. / Koeneman, Kenneth S.; Kao, Chinghai; Ko, Song Chu; Yang, Ling; Wada, Yoshitaka; Kallmes, David F.; Gillenwater, Jay Y.; Zhau, Haiyen E.; Cluing, Leland W K; Gardner, Thomas.

In: World Journal of Urology, Vol. 18, No. 2, 2000, p. 102-110.

Research output: Contribution to journalArticle

Koeneman, KS, Kao, C, Ko, SC, Yang, L, Wada, Y, Kallmes, DF, Gillenwater, JY, Zhau, HE, Cluing, LWK & Gardner, T 2000, 'Osteocalcin-directed gene therapy for prostate-cancer bone metastasis', World Journal of Urology, vol. 18, no. 2, pp. 102-110.
Koeneman KS, Kao C, Ko SC, Yang L, Wada Y, Kallmes DF et al. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World Journal of Urology. 2000;18(2):102-110.
Koeneman, Kenneth S. ; Kao, Chinghai ; Ko, Song Chu ; Yang, Ling ; Wada, Yoshitaka ; Kallmes, David F. ; Gillenwater, Jay Y. ; Zhau, Haiyen E. ; Cluing, Leland W K ; Gardner, Thomas. / Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. In: World Journal of Urology. 2000 ; Vol. 18, No. 2. pp. 102-110.
@article{f6540e8f9f554fb58c456ff38b51ec1c,
title = "Osteocalcin-directed gene therapy for prostate-cancer bone metastasis",
abstract = "Osteocalcin (OC) is a major noncollagenous bone protein whose expression is limited almost exclusively to osteotropic tumors and mature calcified tissue (differentiated osteoblasts). The function of OC, a highly conserved gamma-carboxyglutamic acid-containing protein, relies in part on its ability to bind hydroxyapatite and act as a chemoattractant for bone-resorbing cells. Serum osteocalcin levels are used clinically as an index of active bone turnover. Research in our laboratory has revealed that OC is expressed in several solid tumors, including osteosarcoma and ovarian, lung, brain, and prostate cancers. Evidence arising from reverse-transcription polymerase chain reaction (RT-PCR; detection of OC mRNA), immunohistochemical staining (detection of OC protein), and transient transfection and reporter assay (detection of OC mRNA transcription) reveals that OC expression is up-regulated in numerous solid tumors, with its expression being further elevated in androgen-independent prostate cancers. A recombinant, replication-defective adenovirus, Ad-OC-TK (OC promoter-driven herpes-simplex-virus thymidine kinase) was constructed and, when combined with the appropriate prodrug, either ganciclovir (GCV) or acyclovir (ACV), was found to be effective at destroying prostate-cancer cell lines in vitro and prostate tumor xenografts in vivo in both subcutaneous and bone sites. Additionally, via use of the OC promoter the supporting bone stromal cells are cotargeted when the prostate cancer interdigitates with bone stroma at the metastatic skeletal sites. Thus, maximal tissue-specific cell toxicity is achieved by the interruption of cellular communication between the prostate cancer and the bone stroma. We describe herein the preclinical foundation as well as the design and implementation of an ongoing phase I clinical trial at the University of Virginia that targets androgen-independent metastatic prostate cancer using the Ad-OC-TK vector.",
author = "Koeneman, {Kenneth S.} and Chinghai Kao and Ko, {Song Chu} and Ling Yang and Yoshitaka Wada and Kallmes, {David F.} and Gillenwater, {Jay Y.} and Zhau, {Haiyen E.} and Cluing, {Leland W K} and Thomas Gardner",
year = "2000",
language = "English (US)",
volume = "18",
pages = "102--110",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Osteocalcin-directed gene therapy for prostate-cancer bone metastasis

AU - Koeneman, Kenneth S.

AU - Kao, Chinghai

AU - Ko, Song Chu

AU - Yang, Ling

AU - Wada, Yoshitaka

AU - Kallmes, David F.

AU - Gillenwater, Jay Y.

AU - Zhau, Haiyen E.

AU - Cluing, Leland W K

AU - Gardner, Thomas

PY - 2000

Y1 - 2000

N2 - Osteocalcin (OC) is a major noncollagenous bone protein whose expression is limited almost exclusively to osteotropic tumors and mature calcified tissue (differentiated osteoblasts). The function of OC, a highly conserved gamma-carboxyglutamic acid-containing protein, relies in part on its ability to bind hydroxyapatite and act as a chemoattractant for bone-resorbing cells. Serum osteocalcin levels are used clinically as an index of active bone turnover. Research in our laboratory has revealed that OC is expressed in several solid tumors, including osteosarcoma and ovarian, lung, brain, and prostate cancers. Evidence arising from reverse-transcription polymerase chain reaction (RT-PCR; detection of OC mRNA), immunohistochemical staining (detection of OC protein), and transient transfection and reporter assay (detection of OC mRNA transcription) reveals that OC expression is up-regulated in numerous solid tumors, with its expression being further elevated in androgen-independent prostate cancers. A recombinant, replication-defective adenovirus, Ad-OC-TK (OC promoter-driven herpes-simplex-virus thymidine kinase) was constructed and, when combined with the appropriate prodrug, either ganciclovir (GCV) or acyclovir (ACV), was found to be effective at destroying prostate-cancer cell lines in vitro and prostate tumor xenografts in vivo in both subcutaneous and bone sites. Additionally, via use of the OC promoter the supporting bone stromal cells are cotargeted when the prostate cancer interdigitates with bone stroma at the metastatic skeletal sites. Thus, maximal tissue-specific cell toxicity is achieved by the interruption of cellular communication between the prostate cancer and the bone stroma. We describe herein the preclinical foundation as well as the design and implementation of an ongoing phase I clinical trial at the University of Virginia that targets androgen-independent metastatic prostate cancer using the Ad-OC-TK vector.

AB - Osteocalcin (OC) is a major noncollagenous bone protein whose expression is limited almost exclusively to osteotropic tumors and mature calcified tissue (differentiated osteoblasts). The function of OC, a highly conserved gamma-carboxyglutamic acid-containing protein, relies in part on its ability to bind hydroxyapatite and act as a chemoattractant for bone-resorbing cells. Serum osteocalcin levels are used clinically as an index of active bone turnover. Research in our laboratory has revealed that OC is expressed in several solid tumors, including osteosarcoma and ovarian, lung, brain, and prostate cancers. Evidence arising from reverse-transcription polymerase chain reaction (RT-PCR; detection of OC mRNA), immunohistochemical staining (detection of OC protein), and transient transfection and reporter assay (detection of OC mRNA transcription) reveals that OC expression is up-regulated in numerous solid tumors, with its expression being further elevated in androgen-independent prostate cancers. A recombinant, replication-defective adenovirus, Ad-OC-TK (OC promoter-driven herpes-simplex-virus thymidine kinase) was constructed and, when combined with the appropriate prodrug, either ganciclovir (GCV) or acyclovir (ACV), was found to be effective at destroying prostate-cancer cell lines in vitro and prostate tumor xenografts in vivo in both subcutaneous and bone sites. Additionally, via use of the OC promoter the supporting bone stromal cells are cotargeted when the prostate cancer interdigitates with bone stroma at the metastatic skeletal sites. Thus, maximal tissue-specific cell toxicity is achieved by the interruption of cellular communication between the prostate cancer and the bone stroma. We describe herein the preclinical foundation as well as the design and implementation of an ongoing phase I clinical trial at the University of Virginia that targets androgen-independent metastatic prostate cancer using the Ad-OC-TK vector.

UR - http://www.scopus.com/inward/record.url?scp=0034168328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034168328&partnerID=8YFLogxK

M3 - Article

C2 - 10854144

AN - SCOPUS:0034168328

VL - 18

SP - 102

EP - 110

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 2

ER -